BioVaxys Technology Corp. Lowers Capital Raise Milestone in Amended Asset Purchase Agreement with Horizon Technology Finance Corp

Reuters

30 May

<a href="https://laohu8.com/S/BVAXF">BioVaxys Technology Corp.</a> Lowers Capital Raise Milestone in Amended Asset Purchase Agreement with <a href="https://laohu8.com/S/HTFB">Horizon Technology Finance Corp</a>

BioVaxys Technology Corp. has announced an update to its Asset Purchase Agreement $(APA)$ with Horizon Technology Finance Corporation concerning the acquisition of former IMV Inc. assets. The amended agreement, dated May 29, 2025, reduces the capital raise milestone required from USD $10 million to USD $2,028,636, which must be met by September 30, 2025. Additionally, BioVaxys will issue share purchase warrants to Horizon and Powerscourt Investments XXV LP as part of the consideration. The Licensing Earn-Out Payments Term has also been extended to August 11, 2033. All other terms of the APA remain unchanged. This announcement reflects BioVaxys's ongoing efforts to finalize the acquisition formalized in February 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovaxys Technology Corp. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN99481) on May 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2539297433"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539297433\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2539297433?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-30 08:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539297433","market":"us","top_or_hot":-1,"title":"BioVaxys Technology Corp. Lowers Capital Raise Milestone in Amended Asset Purchase Agreement with Horizon Technology Finance Corp","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BVAXF\">BioVaxys Technology Corp.</a> Lowers Capital Raise Milestone in Amended Asset Purchase Agreement with <a href=\"https://laohu8.com/S/HTFB\">Horizon Technology Finance Corp</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioVaxys Technology Corp. has announced an update to its Asset Purchase Agreement <a href=\"https://laohu8.com/S/APA\">$(APA)$</a> with <a href=\"https://laohu8.com/S/HTFA\">Horizon Technology Finance Corporation</a> concerning the acquisition of former <a href=\"https://laohu8.com/S/IMVIF\">IMV Inc.</a> assets. The amended agreement, dated May 29, 2025, reduces the capital raise milestone required from USD $10 million to USD $2,028,636, which must be met by September 30, 2025. Additionally, BioVaxys will issue share purchase warrants to Horizon and Powerscourt Investments XXV LP as part of the consideration. The Licensing Earn-Out Payments Term has also been extended to August 11, 2033. All other terms of the APA remain unchanged. This announcement reflects BioVaxys's ongoing efforts to finalize the acquisition formalized in February 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovaxys Technology Corp. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN99481) on May 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioVaxys Technology Corp. Lowers Capital Raise Milestone in Amended Asset Purchase Agreement with Horizon Technology Finance Corp</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioVaxys Technology Corp. Lowers Capital Raise Milestone in Amended Asset Purchase Agreement with Horizon Technology Finance Corp\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-30 08:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BVAXF\">BioVaxys Technology Corp.</a> Lowers Capital Raise Milestone in Amended Asset Purchase Agreement with <a href=\"https://laohu8.com/S/HTFB\">Horizon Technology Finance Corp</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioVaxys Technology Corp. has announced an update to its Asset Purchase Agreement <a href=\"https://laohu8.com/S/APA\">$(APA)$</a> with <a href=\"https://laohu8.com/S/HTFA\">Horizon Technology Finance Corporation</a> concerning the acquisition of former <a href=\"https://laohu8.com/S/IMVIF\">IMV Inc.</a> assets. The amended agreement, dated May 29, 2025, reduces the capital raise milestone required from USD $10 million to USD $2,028,636, which must be met by September 30, 2025. Additionally, BioVaxys will issue share purchase warrants to Horizon and Powerscourt Investments XXV LP as part of the consideration. The Licensing Earn-Out Payments Term has also been extended to August 11, 2033. All other terms of the APA remain unchanged. This announcement reflects BioVaxys's ongoing efforts to finalize the acquisition formalized in February 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovaxys Technology Corp. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN99481) on May 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HRZN","symbol_name":"Horizon Technology Finance Corpo","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL4XYwbw:1","article_id":"2539297433","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539297433","pubTimestamp":1748565645,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioVaxys Technology Corp. Lowers Capital Raise Milestone in Amended Asset Purchase Agreement with Horizon Technology Finance Corp. BioVaxys Technology Corp. has announced an update to its Asset Purchase Agreement  with Horizon Technology Finance Corporation concerning the acquisition of former IMV Inc. assets. The amended agreement, dated May 29, 2025, reduces the capital raise milestone required from USD $10 million to USD $2,028,636, which must be met by September 30, 2025. Additionally, BioVaxys will issue share purchase warrants to Horizon and Powerscourt Investments XXV LP as part of the consideration. The Licensing Earn-Out Payments Term has also been extended to August 11, 2033. All other terms of the APA remain unchanged. This announcement reflects BioVaxys's ongoing efforts to finalize the acquisition formalized in February 2024.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HRZN":"Horizon Technology Finance Corpo","BK4139":"生物科技","IMVIF":"IMV Inc.","BK4135":"资产管理与托管银行"},"translate_title":"BioVaxys Technology Corp.降低了与Horizon Technology Finance Corp修订后的资产购买协议中的融资里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HRZN":0.9,"IMVIF":0.9},"content_text":"BioVaxys Technology Corp. Lowers Capital Raise Milestone in Amended Asset Purchase Agreement with Horizon Technology Finance Corp\n\n\n        BioVaxys Technology Corp. has announced an update to its Asset Purchase Agreement $(APA)$ with Horizon Technology Finance Corporation concerning the acquisition of former IMV Inc. assets. The amended agreement, dated May 29, 2025, reduces the capital raise milestone required from USD $10 million to USD $2,028,636, which must be met by September 30, 2025. Additionally, BioVaxys will issue share purchase warrants to Horizon and Powerscourt Investments XXV LP as part of the consideration. The Licensing Earn-Out Payments Term has also been extended to August 11, 2033. All other terms of the APA remain unchanged. This announcement reflects BioVaxys's ongoing efforts to finalize the acquisition formalized in February 2024.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovaxys Technology Corp. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN99481) on May 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}